四天三笔跨国药企交易，潜在最高总额超过180亿美元。 2026年10月2日，诺华与中国生物科技公司艾博生物达成推进RNA疗法的授权及许可选择权协议，获得ABO2203管线（mRNA编码CD19xCD3 ...

孩子无法选择父母，正如父母也无法主动挑选孩子。但如今，一家美国公司号称能为寻求辅助生殖的夫妻筛选“更好”的胚胎。 近日，美国基因组学创业公司 Nucleus Genomics 在其研究平台 Nucleus Labs ...

动物实验显示，多达90%的受试动物在治疗6个月后，体内表面抗原已检测不到，达到了人类乙肝功能性治愈指标；更令人振奋的是，这项疗法的全球1/2期人体临床试验，已经在新西兰和中国香港正式启动，1月已完成首例给药！

Gene-editing techniques could soon allow researchers to replace entire genes and engineer complex cellular circuits — if the ...

CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310 ®, its ...

CRISPR-Cas9 has transformed the life sciences by giving researchers a seemingly simple tool for cutting DNA at chosen ...

CRISPR-Cas9 removed an extra chromosome 21 from some Down syndrome cells in the lab. Learn what the 30.6% result means and ...

Screening ionisable lipids with a gene-editor-sized RNA identified LC-1, an LNP component that retained potency as cargo ...

A new commentary in Discover Plants argues that genomics, CRISPR genome editing, and tissue culture must be integrated with ...

Don't read too much into this year's lackluster performance. Near-term catalysts are firming up.

CRISPR Therapeutics AG remains a long-term Buy, anchored by Casgevy's success and management’s execution in ex vivo gene editing. Click for more on CRSP.

Most of any gains (or lack thereof) from here will be driven by just three factors.